Forecasts data is unavailable for this security.
Consensus recommendation
- 14-Dec-23
- 19-Sep-24
- 17-Oct-24
- 14-Nov-24
- 21-Nov-24
Select bar for recommendation details.
Recommendations | 21-Nov-24 | |
---|---|---|
Buy | 3 | |
Outperform | 2 | |
Hold | 1 | |
Sell | 0 | |
Strong Sell | 0 |
Share price forecast in USD
The 6 analysts offering 12 month price targets for Xeris Biopharma Holdings Inc have a median target of 5.00, with a high estimate of 6.60 and a low estimate of 3.00. The median estimate represents a 64.47% increase from the last price of 3.04.
High | 117.1% | 6.60 |
Med | 64.5% | 5.00 |
Low | -1.3% | 3.00 |
Earnings history & estimates in USD
The next earnings announcement is expected on Mar 04, 2025.
Average growth rate | -8.13% |
Average growth rate | +43.41% |
More ▼
Revenue history & estimates in USD
Average growth rate | +3.65% |
Average growth rate | +241.10% |
More ▼